Kyverna Therapeutics (KYTX) Other Non Operating Income (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Other Non Operating Income came in at -$21000.0 in Q1 2026, up 22.22% YoY from -$17181.8 in Q1 2025, and down 223.53% on a QoQ basis from $17000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) Other Non Operating Income (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Other Non Operating Income data on file, last reported at -$21000.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 22.22% year-over-year to -$21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78000.0 (up 14.29% YoY) and the FY2025 annual result came in at -$85000.0, up 5.56% from the prior year.
- Other Non Operating Income fell to -$21000.0 in Q1 2026, from $17000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $17000.0 in Q4 2025 to a low of -$53000.0 in Q3 2025.
- A 4-year average of -$19230.8 and a median of -$21000.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income plunged 766.67% — and 2025, when it surged 325.0%.
- Tracing KYTX's Other Non Operating Income over 4 years: stood at -$32000.0 in 2023, then soared by 112.5% to $4000.0 in 2024, then surged by 325.0% to $17000.0 in 2025, then tumbled by 223.53% to -$21000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$21000.0 (Q1 2026), $17000.0 (Q4 2025), and -$53000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18,000.00 |
| Mar 31, 2026 | -21,000.00 |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | -53,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -27,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | -45,000.00 |
| Jun 30, 2024 | -23,000.00 |
| Mar 31, 2024 | -26,000.00 |
| Dec 31, 2023 | -32,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -7,000.00 |
| Mar 31, 2023 | -3,000.00 |